Noninvasive Prenatal Diagnostics Market Report

Noninvasive Prenatal Diagnostics Market Analysis, Market Size, Application Analysis, Regional Outlook, Competitive Strategies, and Forecasts, 2015 To 2022

Format: PDF  |  Report ID: GVR2062

The global market for non-invasive prenatal diagnostics is expected to witness lucrative growth over the forecast period. Key driver escalating the growth of this market is the elimination of miscarriage risk due to non-invasiveness. Other factors promoting the application of the non-invasive prenatal diagnostics market include increasing accuracy and safety in detection of chromosomal disorders, growing population of pregnant women and rising awareness of the technology. Various chromosomal disorders such as Down syndrome, Edwards’s syndrome, Turner syndrome and Patau syndrome can be detected using this diagnostic system. Traditional prenatal screening and diagnostics methods are expected to turn obsolete for testing high risk pregnant women, thereby propelling the growth of the market. Furthermore, the application of these diagnostic methods in low risk pregnancies along with high risk ones are expected to expand the market, hence boosting the growth of non-invasive prenatal diagnostics globally. Presence of stringent guidelines over the non-invasive prenatal diagnostic tests is expected to instill confidence in the new technology, thereby facilitating its spurring growth. American Congress of Obstetricians and Gynecologists (ACOG), Japan Society of Obstetrics and Gynecology and various other regulatory bodies conducting clinical studies and providing approvals for utilization of these techniques is anticipated to fuel the growth of non-invasive prenatal diagnostics market.

The non-invasive prenatal diagnostics market is segmented on the basis of tests which include PrenaTest, BambniTest, NIFTY (Non-invasive fetal trisomy test), Harmony, verifi, informaSeq, Panorama, MaterniT21 PLUS, informaSeq and VisibiliT. MaterniT21 plus held the largest share of the market in 2013 due to being the first of its kind diagnostic system. Panorama and verifi tests are anticipated to witness the fastest growth in the non-invasive prenatal diagnostics market during the forecast period owing to their higher accuracy and safety along with rising demand for these tests. Increasing marketing strategies and market penetration by the companies further promote the growth of these tests. NIFTY is expected to witness lucrative growth in Asia Pacific during the forecast period due to its recent approval by CFDA (China Food and Drug Administration) in 2014.

North America held the largest share of the non-invasive prenatal diagnostics market in 2013 and is anticipated to retain its dominance during the forecast period. MaterniT21, the foremost non-invasive prenatal diagnostic test was launched in the U.S. and the four key players of the market are domiciled in the U.S. Rising penetration of the testing procedures, increasing efforts of alliances between companies and hospitals in the region are the major drivers for the dominance. Furthermore, the rising high risk pregnancies and increasing average age for child bearing leading to development of chromosomal disorders are the impact rendering drivers for the region. Europe is expected to follow North America in terms of revenue contribution due to increasing penetration of the companies and rising approvals by the European commission organizations. Asia Pacific and Middle East are expected to witness the fastest growth during the forecast period due to increasing efforts towards marketing and positioning strategies by companies in the untapped market of the region. Furthermore, rising disposable income, increasing paranoia of to-be mothers for the health of their child and supportive government research initiatives are anticipated to shore up the non-invasive prenatal diagnostics market’s attractiveness.

Major market players for the non-invasive prenatal diagnostics market include LifeCodexx AG, Sequenom, Inc., Cellular Research, Ariosa Diagnostics, Ravgen, Verinata Health, LabCorp, Trovagene, BGI Diagnostics, Natera Inc., and Berry Genomics. Approval of NIFTY (BGI diagnostics) by CFDA makes it the only available non-invasive prenatal test in the region of China. Rising investment in technological advancement such as application of next generation sequencing and improving safety and accuracy are expected to open new avenues for the companies and thrust the growth. The market players are involved in several clinical trials and validation studies which on completion are anticipated to impact the non-invasive prenatal diagnostics market.

 

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA